Band 3
Band 3
Provided by Kirian Claeyé
The newest Partner at ALTIUS, Kirian specialises in intellectual property and regulatory affairs relating to the pharmaceutical field.
His IP work focuses on complex patent litigation, often involving cross-border issues, parallel trade disputes, and support and advice regarding IP portfolio management. His regulatory work spans the fields of launch and marketing strategies, pricing and reimbursement, tendering, advertising, and lifecycle management.
Kirian is a member of the Boalt Hall Alumni Association, (Young) EPLAW, Licensing Executives Society, and the Belgian American Educational Foundation (BAEF).
• “Evoluties in het octrooirecht – Overzicht van rechtspraak 2018-2022”, TBH 2022, 435-489 (co-author)
• “Vrijwaring voor uitwinning en intellectuele eigendom” in B. Tilleman & B. Devolder, Weens Koopverdrag, Brugge, Die Keure, 2022, pp. 551-618 (co-author)
• “Pharmaceutical IP and Competition law in Belgium: Overview”, Thomson Reuters, 1 August 2021 (co-author)
• “Must AstraZeneca supply the EU with sufficient COVID-19 vaccines?”, ILO Healthcare & Life Sciences, 10 February 2021 / Mondaq, 13 April 2021
• “Belgium” in J. Bühling, Patent Protection for Second Medical Uses, The Netherlands, Kluwer, 2020 (co-author)
• The Pharma Legal Handbook: Belgium, PharmaBoardroom 2020 (co-author)
• “Evoluties in het octrooirecht – Overzicht van rechtspraak 2014-2018”, TBH-RDC 2018, 747-798 (co-author)
Additionally Kirian regularly speaks at conferences and seminars, is host of ALTIUS’ annual Pharma Law Seminar, and in charge of ALTIUS’ two-monthly Life Sciences Sessions.
Provided by Chambers
Kirian Claeyé has an impressive work portfolio advising high-profile pharmaceutical companies on patent infringement cases. He has further experience in the TMT sector.
Kirian Claeyé acts for major pharmaceutical clients on pricing and reimbursement issues, as well as tendering and regulatory advice.
Provided by Chambers
Kirian Claeyé is very good with the details of legislation and procedures.
Kirian Claeyé has extensive knowledge of case law and procedural law.
He is very responsive, dedicated and flexible, which is why we love him.
Kirian has a strategic mindset while being a very good and clear communicator. He is very responsive and always quick to provide thoughtful input that is actionable.
Kirian Claeyé is a brilliant lawyer with encyclopaedic knowledge of Belgian life sciences regulations and good business acumen. He is our go-to lawyer.
Kirian Claeyé is fast, to the point and clear, and his advice actually matters and enables growth.
Kirian Claeyé is very good with the details of legislation and procedures.
Kirian Claeyé has extensive knowledge of case law and procedural law.
He is very responsive, dedicated and flexible, which is why we love him.
Kirian has a strategic mindset while being a very good and clear communicator. He is very responsive and always quick to provide thoughtful input that is actionable.
Kirian Claeyé is a brilliant lawyer with encyclopaedic knowledge of Belgian life sciences regulations and good business acumen. He is our go-to lawyer.
Kirian Claeyé is fast, to the point and clear, and his advice actually matters and enables growth.
9 items provided by ALTIUS
Belgian Parliament has adopted urgent 2026 healthcare budget measures: impact on the pharma industry
Over the Christmas break, the Belgian Parliament adopted an urgent law with several measures linked to the approved 2026 healthcare budget, with effect from 1 January 2026. The law is intentionally limited to provisions that must enter into force immediately to ensure that the required savings ...
EU Reaches Pharma Package Deal: Key Changes at a Glance
On 11 December 2025, following overnight negotiations, the Council and the European Parliament announced a political agreement on the long-awaited Pharma Package (see here). The reform seeks to update the EU’s pharmaceutical rulebook to facilitate access to safe and affordable treatments ...
Belgian Constitutional Court strikes down pharma industry ‘unavailability contribution’
The Belgian Constitutional Court (“CC”), on 6 November 2025, annulled some provisions of the Law of 18 May 2024 containing various provisions on health and finance, striking down the pharma industry ‘unavailability contribution’.
The new Belgian government’s public health policy: 10 key take-aways for pharma policy
The Belgian government’s new public health policy, “More money for health, more health for our money,” outlines key measures affecting the pharmaceutical industry. These changes bring both challenges and opportunities for pharma companies in Belgium. Here's a brief overview of ten key impacts.
CJEU’s DocMorris Ruling: where is the line for pharmaceutical advertising?
The CJEU case Apothekerkammer Nordrhein v. DocMorris NV (C-517/23) clarifies the limits of national restrictions on pharmaceutical advertising under EU law, balancing consumer protection with internal market freedoms.
CJEU balances strict obligations for wholesalers of medicines with proportional penalties
The CJEU clarified strict rules for medicine wholesalers, emphasizing sourcing from authorized suppliers and proportional penalties for breaches. Wholesalers must ensure compliance with EU health standards and maintain accessible information during inspections.
The 5 major changes in Belgian pharma law of 2023
Both the Belgian legislator and government have played an active role in 2023 when it comes to pharma legislation, which has led to a number of changes in the legal framework. In this article, we look back and discuss five noteworthy developments in Belgian pharma law.
Belgian Medicines Agency announces stricter monitoring of negative formulations on medicines packagi
On 17 May 2023, the Belgian Medicines Agency (FAMHP) announced that marketing authorisation holders (MAHs) have three years to comply with the prohibition of “negative formulations” on the packaging of medicinal products for human use.
CJEU interprets the concept of a global MA strictly
On 16 March 2023, in Joined Cases C‑438/21 P to C‑440/21 P, the Court of Justice of the European Union (CJEU) interpreted the concept of a ‘global marketing authorisation’.
Belgian Parliament has adopted urgent 2026 healthcare budget measures: impact on the pharma industry
Over the Christmas break, the Belgian Parliament adopted an urgent law with several measures linked to the approved 2026 healthcare budget, with effect from 1 January 2026. The law is intentionally limited to provisions that must enter into force immediately to ensure that the required savings ...
EU Reaches Pharma Package Deal: Key Changes at a Glance
On 11 December 2025, following overnight negotiations, the Council and the European Parliament announced a political agreement on the long-awaited Pharma Package (see here). The reform seeks to update the EU’s pharmaceutical rulebook to facilitate access to safe and affordable treatments ...
Belgian Constitutional Court strikes down pharma industry ‘unavailability contribution’
The Belgian Constitutional Court (“CC”), on 6 November 2025, annulled some provisions of the Law of 18 May 2024 containing various provisions on health and finance, striking down the pharma industry ‘unavailability contribution’.
The new Belgian government’s public health policy: 10 key take-aways for pharma policy
The Belgian government’s new public health policy, “More money for health, more health for our money,” outlines key measures affecting the pharmaceutical industry. These changes bring both challenges and opportunities for pharma companies in Belgium. Here's a brief overview of ten key impacts.
CJEU’s DocMorris Ruling: where is the line for pharmaceutical advertising?
The CJEU case Apothekerkammer Nordrhein v. DocMorris NV (C-517/23) clarifies the limits of national restrictions on pharmaceutical advertising under EU law, balancing consumer protection with internal market freedoms.
CJEU balances strict obligations for wholesalers of medicines with proportional penalties
The CJEU clarified strict rules for medicine wholesalers, emphasizing sourcing from authorized suppliers and proportional penalties for breaches. Wholesalers must ensure compliance with EU health standards and maintain accessible information during inspections.
The 5 major changes in Belgian pharma law of 2023
Both the Belgian legislator and government have played an active role in 2023 when it comes to pharma legislation, which has led to a number of changes in the legal framework. In this article, we look back and discuss five noteworthy developments in Belgian pharma law.
Belgian Medicines Agency announces stricter monitoring of negative formulations on medicines packagi
On 17 May 2023, the Belgian Medicines Agency (FAMHP) announced that marketing authorisation holders (MAHs) have three years to comply with the prohibition of “negative formulations” on the packaging of medicinal products for human use.
CJEU interprets the concept of a global MA strictly
On 16 March 2023, in Joined Cases C‑438/21 P to C‑440/21 P, the Court of Justice of the European Union (CJEU) interpreted the concept of a ‘global marketing authorisation’.